載入...
Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014
Cefepime-tazobactam (WCK 4282) is currently under clinical development for use at a dosage of 2 g/2 g every 8 h. A total of 7,981 isolates were collected from 146 medical centers (39 countries) in 2014 as a part of the SENTRY Antimicrobial Surveillance Program, and their susceptibilities to cefepime...
Na minha lista:
| 發表在: | Antimicrob Agents Chemother |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society for Microbiology
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5365660/ https://ncbi.nlm.nih.gov/pubmed/28137811 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02409-16 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|